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Background: A pancreaticoduodenectomy (PD) offers the only chance of a cure for pancreatic cancer
and can be performed with low mortality and morbidity. However, little is known about outcomes of a PD
in octogenarians.
Methods: Differences in two groups of patients (Group Y, <80 and Group O, 80 year-old) who
underwent a PD for pancreatic adenocarcinoma were analysed. Study end-points were length of post-
operative stay, overall morbidity, 30-day mortality and overall survival.
Results: There were 175 patients in Group Y (mean age 64 years) and 25 patients in Group O (mean age
83 years). Octogenarians had worse Eastern Cooperative Oncology Group (ECOG) Performance Status
(PS 1: 90% vs. 51%) and American Society of Anesthesiology (ASA) score (>2: 71% vs. 47%). The two
groups were similar in underlying co-morbidities, operative time, rates of portal vein resection, intra-
operative complications, blood loss, pathological stage and status of resection margins. Octogenarians
had a longer post-operative stay (20 vs. 14 days) and higher overall morbidity (68% vs. 44%). There was
a single death in each group. At a median follow-up of 13 months median survival appeared similar in the
two groups (17 vs. 13 months).
Conclusions: As 30-day mortality and survival are similar to those observed in younger patients, a PD
can be offered to carefully selected octogenarians.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer deaths in
the United States. The American Cancer Society reported that in
2010 more than 35 000 patients died of pancreatic cancer.1
Advanced age is a risk factor for pancreatic adenocarcinoma.
The incidence of pancreatic cancer is 29 per 100 000 in patients
younger than 65 years compared with 91 per 100 000 in patients
80 to 84 years old.2
The number of elderly in the US is rapidly growing. Americans
older than 85 years are in fact the most rapidly growing segment
of the elderly population, and will account for 5% of the overall
population by 2050.3
Surgical resection remains the only treatment with curative
potential for pancreatic adenocarcinoma. As the population ages,
more octogenarians will be diagnosed with pancreatic cancer and
referred to surgeons for curative resection.
Many reports have found acceptable morbidity and mortality
after a pancreaticoduodenectomy (PD) in patients over 70 years
of age.4–10 However, only few authors have examined outcomes of
a PD in patients aged 80 years and older.2,11–14
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In the present study, short-term outcomes and long-term sur-
vival after a PD for pancreatic adenocarcinoma in patients 80
years and older were analysed.
Methods
After Institutional Review Board (IRB) approval, we performed
a retrospective review of patients operated on for pancreatic
adenocarcinoma between 1990 and 2009 at NYU Medical Center.
Patients referred to our Institution with pancreatic cancer are
evaluated by a multidisciplinary team composed of surgical
oncologists, gastroenterologists, medical oncologists, radiation
oncologists and gastro-intestinal pathologists. Treatment is then
customized according to stage and pathological features as well
to patient’s conditions. Typically, patients with resectable or
borderline resectable patients are offered surgery if their Eastern
Cooperative Oncology Group (ECOG) performance status is 2 or
lower. Few exceptions have been made over the course of the
study period, based on the subjective assessment of the operating
surgeon.
In order to minimize confounding factors, we excluded from
the current analysis peri-ampullary lesions other than pan-
creatic adenocarcinoma (bile duct cancers, duodenal cancers
and ampullary tumours) as well as non-invasive intra-ductal
papillary mucinous neoplasms and neuroendocrine tumours.
Data collected included patient demographics, pre-operative
co-morbidities, social history, tumour stage and histo-
pathological features, peri-operative events and complications,
and status of disease at follow-up. Chart reviews were per-
formed solely by experienced clinicians and recorded on stan-
dardized forms. Ambiguities in any data points were discussed
by the study committee, researched, reviewed and corrected.
Data were entered into a secure web-based data entry
system.
From our comprehensive pancreatic adenocarcinoma data-
base consisting of 248 patients, we identified 200 patients who
underwent a PD.
We then categorized study patients into two groups,
according to age at the time of surgery: Group Y (<80 year-old)
and Group O (80 year-old). Variables analysed in the two
groups included demographic data, intra- and post-operative
outcomes.
Differences between groups were evaluated by univariate analy-
ses using the chi-square and independent samples t-test for
categorical and continuous data, respectively. Survival analyses
were performed using Kaplan–Meier curves with log rank tests for
significance.
All statistics performed were two-sided and declared at
the 5% significance level. Statistical analyses were performed
with PASW Statistics v.17.0.2 (SPSS Inc., Chicago, IL,
USA).
The study end-points were length of stay, overall morbidity
and 30-day mortality.
Results
During the period of 1990 to 2009, 248 patients were operated on
for pancreatic adenocarcinoma at the NYU Langone Medical
Center. For the present study, our database for patients who
underwent a PD was queried.
Patient demographics and co-morbidities
The present study population included 99 men and 101 women
with a mean age of 66.7 11.5 years (range 31–89) at the time of
surgery. Table 1 describes the demographics and co-morbidities of
the two study groups. Patients in Group Y had mean age of 64.4
years, as opposed to 83.1 years in Group O. There were no differ-
ences in term of gender composition (male 47.4% vs. 64.0%,
P = 0.13).
Table 1 Baseline characteristics of study patients
Group Y Group O P
<80 years 80 years
175 (87.5%) 25 (12.5%)
Demographics
Male gender 83 (47.4%) 16 (64.0%) 0.13
Age (mean  SD) 64.4  10.3 83.1  2.4 –
Comorbidities and risk factors
ECOG Performance Status
0 62 (49.2%) 2 (10.0%) <0.01
1 44 (34.9%) 6 (30.0%)
2 17 (13.5%) 10 (50.0%)
3 2 (1.6%) 2 (10.0%)
4 1 (0.8%) 0
ASA score
1 7 (4.1%) 0 <0.01
2 83 (48.5%) 7 (29.2%)
3 73 (42.7%) 10 (41.7%)
4 8 (4.7%) 7 (29.2%)
Hypertension 68 (38.9%) 15 (60%) 0.052
Coronary artery disease 22 (12.6%) 5 (20.0%) 0.34
COPD 11 (6.3%) 1 (4.0%) 0.89
Diabetes mellitus 37 (21.1%) 3 (8.0%) 0.42
Chronic kidney disease 8 (4.6%) 3 (12.0%) 0.14
Any major comorbidity 88 (50.3%) 17 (68.0%) 0.13
Pre-operative lab
Albumin (gm/dl) 3.8 3.6 0.14
Creatinine (mg/dl) 0.9 1.0 0.01
Haemoglobin (g/dl) 13.0 13.3 0.76
Bilirubin (mg/dl) 6.5 7.4 0.60
Glucose (mg/dl) 137 128 0.60
SD, standard deviation; ECOG, Eastern Cooperative Oncology Group;
ASA, American Society of Anestesiology; COPD, chronic obstructive
pulmonary disease.
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ECOG Performance Status (PS) and American Society of
Anesthesiology (ASA) scores were worse in the octogenarians
group (ECOG 0: 49.2% vs. 10%, P < 0.01; ASA 3–4: 47.4% vs.
70.9%, P < 0.01). However, there were no major differences in the
incidence of specific comorbidities, and the rates of patients with
at least one major comorbiditiy were similar between groups
(50.3% vs. 68.0%, P = 0.13). Levels of creatinine appeared slightly
increased in Group O (0.9 vs. 1.0, P = 0.01).
Intra-operative outcomes (Table 2)
Table 2 describes intra-operative and post-operative outcomes for
the two study groups. No differences were noted in terms of length
of surgery, rates of portal vein resection, intra-operative organ
injury, blood losses and number of units of blood transfused.
Pathology (Table 3)
All patients included in this study were operated on for pancreatic
adenocarcinoma. Overall resection margins were negative in 68%
of the cases, without differences between groups. Pathological
staging was performed according to the Seventh Edition of the
Cancer Staging Manual edited by the American Joint Committee
on Cancer (AJCC). The vast majority of cancers were in stage IIA
and IIB, without significant differences within groups. Differen-
tiation was well to moderate in 43.5% of our study population and
poor in 52.5%.
Post-operative outcomes (Table 4 and Fig. 1)
There was a single death in each group (P = 0.23).
Overall morbidity was increased in Group O (44.0% vs. 68.0%,
P = 0.03).
No differences were noted in terms of number of units of blood
transfused post-operatively. Length of post-operative stay was
longer in elderly patients (13.7 days vs. 20 days, P = 0.01).
Follow-up was available for 179 patients (89.5% of our
population). At median follow-up of 13 months (35 months for
survivors), 165 (92%) patients were deceased. The median overall
survival, 1-year survival and 5-year survival were 17.3 months,
68.2%, 4.5% for older patients compared with 13.1 months,
51.3% and 5.8% in younger patients (P = 0.06), respectively.
Discussion
A PD is a morbid procedure, but represents the only chance for
cure in patients with adenocarcinoma localized in the pancreatic
head. Advanced age is an aetiological risk factor for pancreas
cancer. Previous population studies have shown that people are
living longer, and the segment of the population over 80 years old
is expected to significantly increase in the coming years.3 This
is turn will lead to a greater number of octogenarians with
Table 2 Intra-operative outcomes
Group Y Group O P
<80 years 80 years
175 (87.5%) 25 (12.5%)
Intra-operative
Operative time (minutes) 469 432 0.12
Portal vein resection 6 (3.4%) 1 (4.0%) 1.0
IO organ injury 5 (2.9%) 0 0.39
IO PRBC transfused (units) 1.3 1.2 0.82
EBL (ml) 1020 707 0.13
IO, intra-operative; PRBC, packed red blood cells; EBL, estimated blood
loss.
Table 3 Pathology
Group Y Group O P
<80 years 80 years
175 (87.5%) 25 (12.5%)
Pathology
Stage
Unknown 10 (5.7%) 0 0.49
IA 10 (5.7%) 0
IB 5 (2.9%) 0
IIA 41 (23.4%) 8 (32.0%)
IIB 103 (58.9%) 17 (68.0%)
III 5 (2.9%) 0
IV 1 (0.6%) 0
R status
Unknown 14 (8.0%) 3 (12.0%) 0.79
R0 121 (69.1%) 15 (60%)
R1 38 (21.7%) 7 (28.0%)
R2 2 (1.1%) 0
Grading
Mean 2.5 2.4 0.75
1 10 (5.7%) 0 0.53
2 65 (37.1%) 12 (48%)
3 93 (53.1%) 12 (48.0%)
x 7 (4.0%) 1 (4.0%)
Table 4 Post-operative outcomes
Group Y Group O P
<80 years 80 years
175 (87.5%) 25 (12.5%)
Post-operative outcomes
Length of post-operative stay 13.7 20 0.01
Any complication 77 (44.0%) 17 (68.0%) 0.03
Mortality 1 (0.6%) 1 (4.0%) 0.23
PO PRBC 0.7 0.9 0.52
Median survival (months) 13.1 17.3 0.06
PO, post-operative; PRBC, packed red blood cells.
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potentially resectable pancreas cancer being referred for surgery.
It has been well established that a pancreatic resection can be
performed safely in patients over the age of 70 years, but
there are only five single-institution retrospective studies that
analysed peri-operative outcomes of pancreatic resections in
octogenarians.2,11–13,15 As summarized in Table 5, the patient
population analysed in those reports was very heterogeneous, as
indications for surgery included different types of pancreatic
malignancies and peri-ampullary tumours13,15 as well as benign
pancreatic diseases.2,11–13,15 Furthermore, some of those studies
included both PD and distal pancreatectomy.11,13 Rates of peri-
operative mortality and overall morbidity for octogenarians
appeared similar to younger patients. The only exception
was represented by Makary et al., which reported on 197
octogenarians and 2491 younger controls, and did show a
significantly higher morbidity and mortality in the older
group (41.6% vs. 52.8% and 1.7% vs. 4.1%, respectively, both
P < 0.05).
In our experience overall morbidity was also higher in octoge-
narians than in younger patients (44% vs. 68%, P = 0.03), whereas
P = 0.06
178 94 36 21 12 10 8 4 3 22
Figure 1 Overall survival after a pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma in octogenarians compared with younger
patients
Table 5 Literature review
Author Indication for surgery Operations
performed
Age N Overall
Morbidity
Mortality OS
(months)
Chen et al. 200315 Pancreatic and peri-ampullary malignancy PD only 70–79 82 56% 12% 16
80–89 16 51% 13% 17.6
Makary et al. 200612 Benign and malignant pathology PD only <80 2491 41.6% 1.7% 18
80–89 197 52.8%* 4.1%* 11*
90 10 50% 0 15
Hardacre et al. 200911 Benign and malignant pathology PD and DP 80 32 66% 0 12
Lee et al. 20102 Benign and malignant pathology PD only <80 703 51.1% 3.8% 18.1
80 74 47.3% 5.4% 11.6*
Hatzaras et al. 201113 Pancreatic malignancy PD and DP <80 490 59% 3.7% 21.9
80 27 52% 3.7% 33.3
Current study Pancreatic adenocarcinoma PD only <80 175 44% 0.6% 13.1
80 25 68%* 4.0% 17.3
*P < 0.05 compared with patients < 80 year old.
OS: overall median survival (only relative to patients operated on for malignancy).
PD, pancreaticoduodenectomy; DP: distal pancreatectomy.
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mortality although higher for octogenarians (0.6% vs. 4.0%) did
not appear statistically different (P = 0.23). A 1-year mortality
similar between study groups (51.3% vs. 68.2%) would suggest
equivalent short-term outcomes between groups. Unfortunately
the performance status of survivors was not systemically recorded
in the post-operative follow-ups, limiting our ability to comment
on differences in post-operative recovery.
Similarly to the other reports listed in Table 5, the main
limitation of our study is its retrospective nature. Two strategies
to minimize the well-known difficulties in capturing accurately
all the details of the retrospective morbidity data were employed.
First, it was decided to exclude from the analysis the incidence
of individual complications (e.g. pneumonia, bleeding and
pancreatic leak) that could have been overlooked in a thorough
yet retrospective review of medical records. On the other hand,
identifying whether a patient had any sort of post-operative
morbidity (i.e. overall morbidity) was accurate and reliable as
a statement specifying whether the post-operative course had
been uncomplicated or complicated is required in our discharge
summary, and therefore prospectively recorded. Second, as
the date of the operation and date of discharge from the hospital
are always reported in administrative records, the objectively
recorded length of stay as an additional surrogate for post-
operative morbidity was used. The finding of a longer hospitals
stay for octogenarians (13.7 vs. 20 days, P = 0.01) supports
the validity of the present observed increased morbidity in
octogenarians.
The present study, similar to the others mentioned above, only
included patients who underwent a resection. This represents an
element of selection bias, in so far as the selection of patients
chosen to undergo a PD. In our experience patients in Group O
had worse pre-operative ECOG performance status and ASA score
compared with Group Y, and tumours with a similar AJCC stage.
Nevertheless, it is certainly plausible that the surgeons selected
the octogenarians most likely to do best after an operation
(those with small volume disease and good overall health status)
while referring unfit patients to best supportive care or systemic
chemotherapy.
With a median follow-up of 35 months for pancreatic cancer
survivors, our database has likely captured most of the cancer-
related events. It was found that long-term survival was longer for
Group O (median OS 13.1 vs. 17.3 months), although this felt
short of statistical significance (P = 0.06). Prior to the present
study, only Lee et al. analysed survival of octogenarians undergo-
ing a PD for pancreatic adenocarcinoma and reported findings
opposite to ours (shorter survival in the elder group: 18.1 vs. 11.6
months, P < 0.01). There is no clear explanation for these differ-
ences between the studies; given the retrospective nature of these
reports, it is likely that selection bias may have played a role. As
summarized in the last column of Table 5 other authors have
also reported on long-term outcomes; however, interpretation of
these data are difficult as patients with a different histology were
included in the survival analyses.
Globally, these studies show that pancreatic resection for pan-
creatic adenocarcinoma or other malignancy can be performed
safely and with acceptable complication rates in well-selected
octogenarians. Extremely advanced age should not be considered
an absolute contraindication to PD, especially in case of malig-
nancy, as survivals may be comparable to those observed in
younger patients.
Future research should focus on predicting what patients will
do well after a PD. In 2009, the Veteran Administration Surgical
Quality Improvement Program (VASQIP) released an online risk
calculator that estimates 30-day mortality after specific general
and subspecialty procedures of moderate or greater complexity.16
Use of the VASQIP Mortality Calculator (VMC) should facilitate
pre-operative risk stratification and informed consent. However,
the VMC does not provide prediction of morbidity, and its use has
not been validated outside the VA.
Frailty is an entity that has recently been identified as a marker
of physiological reserve in elderly patients and is unique from
comorbidity and disability.17 Further prospective studies are nec-
essary to determine whether a measurement of frailty may help
clinicians in surgical decision-making for elderly patients.
Conclusions
The expected increase in the octogenarian population will
result in a significant increase in the number of 80 year olds
being diagnosed with pancreatic adenocarcinoma and referred
to the surgeon for consideration of a PD. Multidisciplinary
treatment planning, and careful selection for surgery is critical in
managing these, and all pancreatic cancer patients. However,
surgery, the only chance for cure, should not be denied to
octogenarians with pancreatic adenocarcinoma, solely based on
chronological age.
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